BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -90.3% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $206 | -37.6% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $330 | +101.2% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $164 | – | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 100 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | +100.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 189,935 | $311,494 | 0.08% |
| ABNER HERRMAN & BROCK LLC | 280,000 | $459 | 0.07% |
| Weaver Consulting Group | 65,947 | $108,153 | 0.06% |
| S.C. Financial Services, Inc. | 25,372 | $41,610 | 0.03% |
| JMAC ENTERPRISES LLC | 40,430 | $66,305 | 0.02% |
| Weaver Consulting Group | 53,500 | $10,047 | 0.01% |
| IFP Advisors, Inc | 26,650 | $139 | 0.00% |
| Bangor Savings Bank | 4,000 | $7 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $4,920 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 19,098 | $31,321 | 0.00% |